Cardiac Monitors in Massachusetts

InfoBionic, Inc. is a virtual cardiac telemetry company specializing in AI-enabled remote cardiac monitoring. The company's flagship product, MoMe ARC® (Advanced Remote Cardiology), is recognized as the gold standard in remote cardiac ECG monitoring and represents the first platform to market with hospital-grade continuous monitoring capability deployable from nearly any location. The MoMe ARC® platform integrates advanced artificial intelligence to enhance clinical workflow, detect previously undetected cardiac anomalies, and enable rapid interventions at scale. InfoBionic offers a comprehensive suite comprising MoMe Solutions (AI-enabled ECG analysis), MoMe Sensors (interchangeable, tiered biosensor lead sets configurable for varying acuity levels from high-acuity diagnostics to portable monitoring), and MoMe Analytics™ (business intelligence and AI-embedded analytics for cardiac care operations). The company targets cardiology practices, cardiologists, electrophysiologists, medical leaders, hospital systems, and virtual health programs. InfoBionic has received FDA clearance for its MoMe ARC® Patch (announced August 2025), affirming regulatory compliance and clinical safety. The platform transforms cardiac data into actionable clinical insight through proprietary AI algorithms focused on arrhythmia detection, atrial fibrillation monitoring, and congenital heart disease assessment. Products are designed to improve patient quality of life through earlier interventions, enhance operational efficiency across departments, and support both enterprise and telehealth deployment models.

Podimetrics, Inc. develops remote monitoring solutions for diabetic foot health and complex diabetes care management. The company manufactures the SmartMat™ (and next-generation SmartMat+), an FDA-cleared wearable platform that detects early signs of foot inflammation and diabetic foot ulcers through daily 20-second contact monitoring. The SmartMat collects thermal and pressure data to identify high-risk individuals before complications emerge. The solution integrates remote monitoring technology with personalized clinical support and timely alerts to enable early intervention. Podimetrics targets payors, healthcare systems, and employers managing high-risk diabetic populations. Clinical evidence supports reductions in amputations, hospitalizations, and diabetes-related complications. The company emphasizes that 85% of diabetic foot ulcers are preventable, and one-third of diabetes spending addresses lower-extremity complications. The platform combines hardware, cloud-based analytics, and clinical outreach services to support complex diabetes care workflows and improve outcomes while reducing utilization costs.

Anumana Inc. is a cardiovascular AI software company headquartered in Cambridge, MA, developing FDA-cleared algorithms for ECG analysis and cardiac disease detection. Founded in 2021 as a joint effort between Mayo Clinic and nference, the company specializes in ECG-AI®, a proprietary platform that analyzes 12-lead electrocardiograms using deep learning to identify cardiac pathology invisible to clinicians. The flagship algorithm detects low ejection fraction (LEF) and is clinically validated on approximately 2.9 million ECG-echo pairs from 676,000+ patients across diverse populations. The platform has received FDA 510(k) clearance (K250652) for LEF detection and recent clearances for cardiac amyloidosis and pulmonary hypertension algorithms. Anumana's technology integrates seamlessly into existing EHR systems and ECG management platforms without requiring external data processing—algorithms run on-premises for enhanced data security and privacy. The company's AI engine processes 60,000 ECG data points per study and delivers clinical findings compatible with current cardiology workflow. Product portfolio includes multiple cardiac-focused algorithms in development spanning early disease detection, perioperative imaging, atrial fibrillation risk stratification, hyperkalemia detection, diastolic dysfunction assessment, and cardiomyopathy screening. Clinical evidence published across 100+ peer-reviewed publications in journals including Nature Medicine, JACC, and European Heart Journal. The platform supports EHR orderable creation, HL7 configuration, CPT code assignment, and is eligible for reimbursement in US and EU markets. Anumana serves cardiology practices, hospitals, and integrated health systems seeking AI-assisted ECG interpretation and early identification of at-risk cardiac patients.

ATC Technologies Inc is an ISO 13485 certified medical device manufacturer based in Wilmington, Massachusetts, specializing in contract manufacturing and design of surgical instruments and diagnostic devices since 1989. The company develops electrocautery instruments, biopsy forceps, laparoscopy tools, pencil electrodes, and handheld electrode probes for surgical and cardiology applications. ATC provides end-to-end services from clinical need definition through design, FDA-regulated testing, approval, manufacturing, and distribution, with a focus on quality assurance, enhanced performance, and patient care outcomes. The company serves as an OEM manufacturer and partner for medical device innovation.

Implicity is a cloud-based digital MedTech software company specializing in AI-driven remote cardiac monitoring and research solutions for healthcare providers. Founded in 2016, the platform centralizes and standardizes cardiac implantable electronic device (CIED) data from multiple manufacturers (Abbott, Biotronik, Boston Scientific, Medtronic, Microport) into a single unified dashboard. The FDA-cleared, CE-marked platform employs patented AI algorithms to filter clinical alerts, reduce false positives by up to 79%, and prioritize clinically relevant events for faster clinical decision-making. Key solutions include vendor-neutral CIED remote monitoring, ILR ECG Analyzer (for Medtronic implantable loop recorders), AF Alert Management, SignalHF Predictive AI for heart failure risk stratification, and advanced research tools for real-time clinical data collection. The platform demonstrates proven clinical impact: 26% reduction in mortality, 4% reduction in hospitalization length, and 85% reduction in unnecessary atrial fibrillation alerts. Implicity serves over 100,000 patients across more than 250 medical facilities in the United States and Europe, with offices in Cambridge, Massachusetts, and Paris, France.

Nova Biomedical is a privately held, globally-leading in vitro diagnostic (IVD) company founded in 1976 and headquartered in Waltham, Massachusetts. The largest privately owned diagnostic company in the United States, Nova Biomedical employs over 1,500 people across manufacturing facilities in Massachusetts and Taipei, Taiwan, serving 110+ countries through its global distributor network. The company specializes in advanced blood testing and analytical instrumentation, with a comprehensive portfolio including critical care blood gas analyzers (StatProfile® Prime series), point-of-care glucose meters (StatStrip®, NovaMax®), cell culture analyzers (BioProfile® Flex), clinical and bioprocessing osmometers, liquid volume verification systems, and automated CSF cell counters. Nova Biomedical serves hospitals, emergency departments, blood banks, biotech/pharmaceutical manufacturers, clinical research laboratories, and veterinary diagnostics markets. The company operates through multiple trusted brand portfolios including Advanced Instruments, BioProfile, StatProfile, StatStrip, Artel, Solentim, and GloCyte, delivering solutions for bioprocessing, clinical diagnostics, and veterinary applications with emphasis on improving patient outcomes and operational efficiency.

TransMedics Group, Inc. is a medical technology company headquartered in Andover, Massachusetts, specializing in organ preservation and transplantation. The company manufactures the Organ Care System (OCS)—an FDA-approved, portable ex vivo perfusion platform that maintains donor organs in a near-physiologic state outside the body. TransMedics offers specialized OCS systems for lung, heart, and liver transplantation, addressing critical limitations of traditional cold storage by reducing ischemic injury, improving organ viability assessment, and enabling long-distance organ retrieval. The company also operates the National OCS Program (NOP), providing comprehensive end-to-end technology and clinical support services to transplant centers, including organ procurement logistics, clinical expertise, and resource optimization. Founded in 1998, TransMedics went public in 2019 and has established itself as a leader in transforming transplant outcomes for patients with end-stage organ failure.

Jali Medical is a leading U.S. distributor of neuromodulation devices and wearable neurotechnologies, headquartered in Framingham, Massachusetts. Founded in 1991 with over 30 years of experience, the company specializes in non-invasive brain stimulation systems for neuroscience research and clinical applications. Jali Medical distributes FDA-cleared Transcranial Magnetic Stimulation (TMS) therapy systems for treating Major Depressive Disorder, along with advanced electroencephalography (EEG) systems, transcranial direct current stimulation (tDCS/tACS) devices, electromyography (EMG) systems, and neuronavigation equipment. The company serves academic institutions, research centers, hospitals, and clinicians nationwide, providing precision-engineered neurotechnology coupled with comprehensive scientific support. Jali Medical offers flexible leasing options for TMS therapy systems and in-person product demonstrations to facilitate clinical adoption and research innovation in neurophysiology and behavioral health applications.

Ablative Solutions, Inc. is a clinical-stage medical device company developing innovative catheter-based treatments for hypertension by targeting the sympathetic nervous system. The company's primary product, the Peregrine System Kit, uses transcatheter perivascular alcohol infusion to deliver dehydrated alcohol to the renal arteries, disrupting overactive renal nerves to reduce blood pressure. Founded in 2011 and based in Wakefield, Massachusetts, Ablative Solutions has raised $149.8 million in funding and is advancing the Peregrine System through clinical trials, including the TARGET BP I Pivotal Trial, toward FDA approval. The company also explores expanded applications of alcohol renal denervation beyond hypertension management.

Elucid Bioimaging develops FDA-cleared cardiovascular imaging analytics software specializing in quantitative plaque assessment from coronary CT angiography (CCTA). The company's flagship product, PlaqueIQ™, employs CT Virtual Histology™ technology to characterize arterial plaque composition non-invasively, leveraging algorithms trained and validated against ground-truth histopathology. PlaqueIQ quantifies and classifies plaque morphology into calcified, non-calcified matrix, and lipid-rich necrotic core (LRNC) components, delivering patient-, vessel-, and lesion-level analysis with high correlation to ex vivo histology (r=0.87–0.99 across plaque types). The software integrates into clinical PACS workflows via DICOM-wrapped PDFs and interactive browser-based reports, enabling physicians to assess coronary and carotid atherosclerosis risk and guide medical versus interventional treatment decisions. Elucid holds FDA 510(k) clearance (K183012, December 2018) and has achieved Category I CPT coding and broad CMS reimbursement as of January 2026. The company also develops FFRCT (fractional flow reserve CT) technology under regulatory pathway. Served markets include cardiology, interventional cardiology, radiology, and cardiovascular research. Clinical validation includes partnership with CVPath Institute and peer-reviewed publications in major cardiovascular literature.